Immunofoco Biotechnology Co. Ltd. reported encouraging early clinical data for its CLDN18.2-targeted CAR T therapy, IMC-002, in heavily pretreated gastric and gastroesophageal junction cancer, adding ...

Boston Scientific Corp.'s Farapoint, its latest pulsed field ablation catheter, received U.S. FDA approval for use as an ...

Previous studies combining molecular techniques and genetic mouse models revealed the functional roles of several microRNAs and long noncoding RNAs (lncRNAs) in metabolic disorders. In particular, the ...

Researchers from Stanford School of Medicine and Yonsei University College of Medicine reported the discovery and preclinical characterization of novel KLHDC2-mediated CDK6-selective degraders.

Tianjin Tianyao Pharmaceuticals Co. Ltd. has identified glucocorticoid receptor (GR) agonists reported to be useful for the treatment of conjunctivitis, asthma, chronic obstructive pulmonary disease, ...

Swiss Rockets AG and Alloy Therapeutics Inc. have signed a master research agreement establishing a multitarget collaboration to discover and develop next-generation radioligand therapeutics (RLTs) ...

Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial ...

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal models. A mutation in the NTM gene was found ...

Hainan Simcere Pharmaceutical Co. Ltd. has described N-myristoyltransferase 1 (NMT1) and NMT2 inhibitors reported to be useful for the treatment of cancer.

Researchers at Iama Therapeutics Srl and Italian Institute of Technology have disclosed solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of Down ...

Bacillus anthracis is a spore-forming soil bacterium that becomes metabolically active when taken up by a host, causing ...

Illumina Inc. presented at the J.P. Morgan 2026 Healthcare Conference on Jan. 13 and introduced what it said is the world's largest genome-wide genetic perturbation dataset, being built to accelerate ...